Atopic Asthma
Atopic asthma is a chronic inflammatory disorder of the airways, characterized by airway hyperresponsiveness, reversible airflow obstruction, and inflammation, which is often triggered by an allergic reaction to environmental allergens. It represents a significant subset of asthma, specifically defined by the presence of atopy, typically identified by a positive skin prick test to at least one common allergen.[1]
Biological Basis
Section titled “Biological Basis”The development of atopic asthma involves a complex interplay of genetic and environmental factors. Genome-wide association studies (GWAS) have identified numerous genetic loci associated with asthma risk, many of which are relevant to atopic asthma. These include genes such asORMDL3, IL1RL1, GSDMB, GSDMA, IL18R1, IL33, IL2RB, HLA-DQ, SMAD3, PDE4D, DENND1B, and IL6R [1], [2]. [3] For instance, a predisposing variant, rs7130588 :G, on chromosome 11q13.5 has been found to be more prevalent in individuals with atopic asthma compared to those with non-atopic asthma.[1] These genetic associations highlight roles in immune regulation, inflammatory pathways, and airway structural integrity.
Clinical Relevance
Section titled “Clinical Relevance”Clinically, atopic asthma is diagnosed based on characteristic respiratory symptoms such as wheezing, shortness of breath, chest tightness, and coughing, coupled with evidence of allergic sensitization. The distinction between atopic and non-atopic asthma is important for treatment strategies, as atopic forms may respond differently to therapies targeting allergic pathways. Genetic insights can contribute to a deeper understanding of disease heterogeneity, potentially leading to more personalized diagnostic and therapeutic approaches.
Social Importance
Section titled “Social Importance”Asthma, including its atopic form, represents a significant public health challenge globally. It affects a substantial portion of the population, with prevalence estimated around 9% in some cohorts.[3] The condition can significantly impair quality of life, leading to school and work absenteeism, and imposes considerable economic burdens on healthcare systems due to long-term management and emergency care. [3]
Limitations
Section titled “Limitations”Study Design and Statistical Power
Section titled “Study Design and Statistical Power”Current genetic studies of atopic asthma often face limitations related to sample size and statistical power, which can restrict the ability to detect novel associations, especially for variants with smaller effect sizes or lower frequencies. For instance, studies with relatively small sample sizes may not achieve genome-wide significance despite observing suggestive associations, potentially leading to false negative results.[4]Furthermore, population-based studies, while valuable, may have reduced power to detect novel associations due to the lower prevalence of asthma compared to case-control designs with an equivalent total sample size.[3]Differences in sample size between cohorts, such as larger childhood asthma analyses compared to adult cohorts, also result in varying statistical power to detect genetic associations.[5]
The replication of findings can also be constrained by methodological inconsistencies. When initial genome-wide association studies (GWAS) utilize detailed longitudinal phenotypic data, but replication cohorts only have cross-sectional measurements, the ability to identify consistent associations, particularly for dynamic traits like bronchodilator response, may be compromised. [6]Additionally, some analyses have focused exclusively on common genetic variants, typically those with minor allele frequencies above 5%, meaning rarer variants that might play a role in asthma susceptibility remain largely untested.[3] While efforts are made to control for genomic inflation, some meta-analyses have not applied corrections for inflation of test statistics, which could potentially impact the accuracy of reported associations. [1]
Phenotypic Definition and Measurement Heterogeneity
Section titled “Phenotypic Definition and Measurement Heterogeneity”The precise definition and consistent measurement of asthma phenotypes across studies present significant challenges. Reliance on self-reported or doctor-diagnosed asthma, even when confirmed by a physician, can introduce misclassification within case groups, potentially diluting genetic signals.[3]Moreover, the phenotype of asthma itself is heterogeneous, characterized by variable age of onset and diverse clinical presentations.[3]Studies focusing on specific asthma subtypes, such as allergic asthma in pediatric clinic settings, may not have findings generalizable to the broader spectrum of asthma.[7]
Measurement inconsistencies also extend to quantitative traits and molecular data. For example, bronchodilator response (BDR) can be measured at a single time point or longitudinally, and discrepancies in these approaches across cohorts may limit the comparability and robustness of replication efforts. [6]Furthermore, when gene expression profiling is conducted in a single tissue type, such as peripheral blood CD4+ lymphocytes, the findings might not fully reflect the complex molecular pathways operating in other relevant tissues involved in asthma pathogenesis.[8]Ideal control populations for asthma-related quantitative traits are also challenging to establish, with general population controls sometimes being significantly younger than cases, potentially leading to conservative results if some controls later develop asthma.[4]
Ancestral Diversity and Generalizability
Section titled “Ancestral Diversity and Generalizability”A significant limitation in understanding the genetic architecture of atopic asthma is the restricted ancestral diversity within many study cohorts. A substantial portion of current GWAS have primarily included individuals of specific ancestries, such as European-American, Hispanic white, non-Hispanic white, Japanese, or Mexican children.[8] This lack of broad ancestral representation limits the generalizability of findings, as genetic risk factors and their effect sizes, as well as gene expression patterns, can vary considerably across different ethnic backgrounds. [8]
While efforts are often made to adjust for population stratification through methods like ancestry-informative markers or principal components analysis, this remains a critical consideration. [2] In some instances, population stratification between cases and controls can be relatively strong, which, if not fully accounted for, could lead to spurious associations or obscure true genetic signals. [4]Expanding research to include more ancestrally diverse populations is essential to identify a comprehensive set of genetic risk factors for atopic asthma and ensure the clinical relevance of discoveries across global populations.
Unaccounted Genetic and Environmental Influences
Section titled “Unaccounted Genetic and Environmental Influences”Despite advancements, a complete understanding of atopic asthma’s etiology remains elusive, partly due to unexplored genetic variation and the complex interplay with environmental factors. The predominant focus on common single nucleotide polymorphisms (SNPs) in GWAS means that rare variants, which may contribute significantly to individual disease risk or explain a portion of the “missing heritability,” are largely unexamined.[3]This gap in variant coverage limits a comprehensive genetic picture of the disease.
Moreover, environmental exposures and their interactions with genetic predispositions are critical yet challenging to fully capture and model. Differences in environmental factors, such as exposure to environmental tobacco smoke (ETS), or other related phenotypic traits like total IgE levels, can vary significantly between study cohorts, introducing potential confounders that are difficult to standardize. [9]While some studies have explored the impact of stratifying analyses by factors like smoking status, the intricate gene-environment interactions that modulate asthma risk are complex and represent a substantial area of ongoing research.[3]A more integrated approach is needed to fully disentangle the genetic and environmental contributions to atopic asthma.
Variants
Section titled “Variants”Genetic variations play a significant role in an individual’s susceptibility to atopic asthma, often influencing immune responses and barrier functions. Several key genes and their single nucleotide polymorphisms (SNPs) have been identified that contribute to the complex etiology of this allergic condition. These variants frequently impact cytokine signaling, antigen presentation, and epithelial integrity, all critical components in the development and progression of atopic asthma.
Variants within genes involved in cytokine signaling, such asIL1RL1, IL18R1, IL33, and TSLP, are strongly associated with atopic asthma. TheIL1RL1 gene encodes the receptor for IL33, a cytokine that promotes Th2-type immune responses, which are characteristic of allergic inflammation. Variations inIL1RL1 and IL18R1, such as those in linkage disequilibrium with rs3771175 , have been broadly linked to asthma and related allergic traits.[10] Similarly, the IL33gene encodes another crucial cytokine that drives allergic inflammation, and SNPs likers3939286 (or nearby variants such as rs1342326 ) have shown significant association with asthma.[11] TSLP (Thymic Stromal Lymphopoietin), encoded by a gene in the vicinity of BCLAF1P1, is an epithelial-derived cytokine that initiates allergic inflammation, and variants such asrs1837253 have been found to have stronger associations with asthma risk.[12]These genetic changes can alter the production or function of these cytokines and their receptors, leading to dysregulated immune responses that predispose individuals to atopic asthma.
The Major Histocompatibility Complex (MHC) region, particularly genes like HLA-DQA1 and HLA-DQB1, is critical for immune recognition and antigen presentation, and SNPs in this region, including rs17843580 , are consistently linked to asthma. TheHLA-DQregion on chromosome 6p21.3 is a well-established locus associated with asthma, with variants influencing the presentation of allergens to T cells, thereby shaping the adaptive immune response.[5] The GSDMB gene, encoding a member of the gasdermin family, is associated with inflammation, and while rs56380902 is a specific variant, related GSDMAvariants have been noted for their strong association with asthma risk.[12]Alterations in these genes can lead to an increased inflammatory state or aberrant immune recognition, contributing to the allergic response seen in atopic asthma.
Other genes implicated in atopic asthma includeFLG, which encodes filaggrin, a protein essential for skin barrier function. Variants like rs61816761 and rs138726443 in or near FLGcan lead to impaired skin barrier integrity, increasing susceptibility to allergen sensitization and the development of atopic conditions, including asthma.[13] Similarly, genes like EMSY (or LINC02757), D2HGDH, SELENOTP1, TPD52L3, and CCDST (which may involve variants such as rs7936312 , rs55646091 , rs1892954 , rs34290285 , rs7370843 , rs141343442 , rs2169287 , rs12123821 , rs1552994 ) are involved in diverse cellular processes ranging from DNA repair to metabolic pathways and protein transport, which, when disrupted by certain variants, can contribute to the overall genetic predisposition to atopic diseases by impacting cellular stress responses or immune regulation. While specific mechanisms for these variants are still being elucidated, their presence suggests a broader genetic landscape influencing asthma susceptibility beyond direct immune mediators.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs7936312 rs55646091 rs1892954 | EMSY - LINC02757 | asthma eosinophil count childhood onset asthma adult onset asthma atopic asthma |
| rs3771175 | IL1RL1, IL18R1 | allergic sensitization measurement asthma atopic asthma |
| rs61816761 rs138726443 | CCDST, FLG | asthma childhood onset asthma allergic disease sunburn vitamin D amount |
| rs3939286 | GTF3AP1 - IL33 | atopic asthma seasonal allergic rhinitis Nasal Cavity Polyp asthma respiratory system disease |
| rs34290285 rs7370843 rs141343442 | D2HGDH | eosinophil percentage of leukocytes eosinophil count eosinophil percentage of granulocytes asthma, allergic disease basophil count, eosinophil count |
| rs56380902 | GSDMB | atopic asthma type 1 diabetes mellitus |
| rs1837253 rs58743367 rs10061842 | BCLAF1P1 - TSLP | eosinophil percentage of leukocytes eosinophil count eosinophil percentage of granulocytes asthma asthma, allergic disease |
| rs12123821 rs1552994 | CCDST | non-melanoma skin carcinoma asthma susceptibility to plantar warts measurement allergic disease mosquito bite reaction itch intensity measurement |
| rs2169287 | SELENOTP1 - TPD52L3 | atopic asthma |
| rs17843580 | HLA-DQA1 - HLA-DQB1 | atopic asthma childhood onset asthma Inhalant adrenergic use measurement age of onset of asthma |
Classification, Definition, and Terminology
Section titled “Classification, Definition, and Terminology”Defining Atopic Asthma and Related Conditions
Section titled “Defining Atopic Asthma and Related Conditions”Atopic asthma is a chronic respiratory condition characterized by a history of physician-diagnosed asthma, often involving reversible airflow obstruction and/or bronchial hyperresponsiveness.[5]The term “atopic” signifies an individual’s genetic predisposition to produce IgE antibodies in response to common environmental allergens, leading to allergic sensitization. This allergic component is central to atopic asthma, distinguishing it from non-atopic forms of the disease.
Related allergic conditions, such as hay fever (also known as allergic rhinitis), are frequently co-morbid with atopic asthma and are often used in research to define allergic status[1]. [3]The broader concept of endophenotypes recognizes the shared genetic and environmental influences across allergic diseases, considering classifications like “atopic dermatitis (AD) and asthma” or “AD no asthma” to better understand complex trait mechanisms.[13]Asthma itself is increasingly understood not as a single disease but as a syndrome comprising various heterogeneous diseases, each potentially with distinct underlying mechanisms and treatment responses.[14]
Operational and Diagnostic Criteria
Section titled “Operational and Diagnostic Criteria”The diagnosis of asthma typically involves a history of physician diagnosis coupled with objective evidence of airway dysfunction, such as reversible airflow obstruction or bronchial hyperresponsiveness.[5]For instance, diagnostic criteria in some studies define asthma by a history of the condition combined with a heightened airway reactivity, demonstrated by a significant improvement in forced expiratory volume in 1 second (FEV1) (e.g., ≥ 12% and ≥ 200 mL) following bronchodilator administration, or by a positive methacholine challenge test (e.g., PC20 ≤ 8 mg/mL).[5]These criteria can be adapted for specific populations, distinguishing between childhood asthma (diagnosis before age 18) and adult asthma (diagnosis after age 18).[5]
Atopy, a key characteristic of atopic asthma, is operationally defined through various measurement approaches, including skin prick testing or specific IgE blood tests. For example, individuals may be considered atopic if their skin reaction to at least one allergen exceeds a certain diameter (e.g., 4 mm)[7] or if specific IgE levels to common food or airborne allergens surpass a threshold (e.g., > 0.7 kUA/l). [15]Control groups in research often exclude individuals with a negative history of allergic diseases or allergic sensitization, confirmed by self-administered questionnaires and negative skin prick test results to a panel of common allergens.[15]Exclusion criteria for healthy controls may also include self-reported asthma without a physician diagnosis, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, chronic cough associated with wheeze, other lung disease, or FEV1 less than 70% of predicted.[3]
Classification and Phenotypic Heterogeneity
Section titled “Classification and Phenotypic Heterogeneity”Asthma is classified to guide management and understand its diverse presentations, often including severity gradations such as mild (intermittent or persistent), moderate, or severe, typically assessed according to established guidelines like the Global Initiative on Asthma (GINA) schema.[7]The recognition of asthma as a heterogeneous syndrome has led to the exploration of various subtypes, moving beyond a singular diagnostic label.[14]
This evolving understanding acknowledges distinct phenotypic presentations, such as “persistent adult phenotypes” [16] and allows for stratified analyses based on factors like smoking status or the presence of co-morbid allergies. [3]For instance, specific subtypes like “asthma with hay fever” are studied to identify unique genetic associations, reflecting a more dimensional approach to characterization rather than strictly categorical definitions.[1]
Signs and Symptoms
Section titled “Signs and Symptoms”Clinical Manifestations and Phenotypes
Section titled “Clinical Manifestations and Phenotypes”Atopic asthma is characterized by a range of respiratory symptoms, often including wheezing, which can manifest as early as the first six years of life.[9]Individuals typically present with physician-diagnosed asthma, often confirmed through self-report or parental questionnaires.[2]The clinical presentation is diverse, encompassing phenotypes such as childhood-onset asthma, asthma with co-occurring atopic dermatitis (AD), and specific forms like “asthma with hay fever” or “asthma but not hay fever”.[17]Severity can range from moderate persistent asthma to more challenging presentations, such as refractory eosinophilic asthma, which may require specific therapeutic approaches.[9]
Diagnostic Assessment and Objective Measures
Section titled “Diagnostic Assessment and Objective Measures”Diagnosis relies on a combination of clinical assessment and objective measures to evaluate respiratory function and atopic status. Physician diagnosis, often based on reported symptoms and medical history, is a primary method for case ascertainment in studies. [2] Objective assessment includes evaluating pulmonary function, testing for bronchial hyperresponsiveness, and measuring bronchodilator reversibility (BDR), which indicates improvement in lung function after administration of a bronchodilator. [6]Furthermore, as atopic asthma is intrinsically linked to allergic sensitization, total serum IgE levels serve as a key biomarker to quantify the degree of atopy, aiding in the comprehensive characterization of the disease.[4]
Heterogeneity and Clinical Significance
Section titled “Heterogeneity and Clinical Significance”The presentation of atopic asthma exhibits significant heterogeneity, with variability in age of onset and disease patterns. While many cases manifest as childhood asthma, onset and relapse can also occur in adult life.[9]The presence of specific allergic comorbidities, such as hay fever or atopic dermatitis, defines distinct clinical phenotypes that can influence diagnostic and management strategies.[17]Understanding these diverse presentation patterns and their associated objective measures is crucial for accurate diagnosis, differential diagnosis against other respiratory conditions, and for predicting the course and severity of the disease in individual patients.
Causes of Atopic Asthma
Section titled “Causes of Atopic Asthma”Atopic asthma is a complex respiratory condition influenced by a combination of genetic predispositions and environmental exposures. The development and manifestation of this trait involve intricate biological pathways, encompassing immune regulation, inflammatory responses, and airway remodeling. Research highlights the polygenic nature of atopic asthma, with numerous genetic variants contributing to individual risk, alongside various external factors and their interactions.
Genetic Susceptibility and Key Loci
Section titled “Genetic Susceptibility and Key Loci”Atopic asthma has a significant genetic component, characterized by its polygenic nature where multiple genetic variants collectively contribute to an individual’s risk. While specific single nucleotide polymorphisms (SNPs) may explain a modest portion of the population variance in asthma risk, additional variance is accounted for by multiple signals across various loci, such as those in theIL1RL1/IL18R1 and HLA regions, as well as the RORA gene. [3]Several specific genetic loci have been consistently implicated in atopic asthma. For example, thers7130588 :G variant on chromosome 11q13.5 has been found to be more prevalent in atopic asthmatic patients, who are typically defined by a positive skin prick test to common allergens. [1]
Further studies have replicated associations with genes such as GSDMB, GSDMA, IL18R1, IL33, and IL2RB, underscoring their roles in asthma susceptibility.[1] The HLA region, particularly HLA-DQ, has been repeatedly confirmed as a risk factor for asthma, including in adult populations.[5] Other important genetic contributions include variants regulating ORMDL3 expression and a deletion on chromosome 17q21, both associated with childhood asthma risk.[1] Additionally, chromosome 9q21.31 has been identified as a susceptibility locus, notably in Mexican children. [7] Gene-gene interactions, such as between rs2041733 and CLEC16A, have also been observed in conditions like atopic dermatitis, which frequently co-occurs with asthma, suggesting complex genetic interplay in atopic diseases.[10]
Environmental Triggers
Section titled “Environmental Triggers”Environmental factors play a crucial role in triggering and exacerbating atopic asthma symptoms, particularly in genetically predisposed individuals. Exposures such as air pollution, including residential ambient ozone, and environmental tobacco smoking have been investigated as potential modifiers of asthma risk.[7]While smoking status is a recognized environmental exposure, it was not found to be a significant predictor of asthma in one Australian sample.[1]
Allergic status, often assessed by the presence of hay fever or other allergic nasal symptoms, is another important environmental modifier for the risk of developing asthma.[3]Exposure to common allergens, which leads to positive skin prick tests, is a defining characteristic of atopic asthma and signifies the immune system’s hypersensitivity to specific environmental agents.[1]The cumulative effect of these various environmental exposures can contribute to airway inflammation and hyperresponsiveness characteristic of atopic asthma.
Gene-Environment Interactions
Section titled “Gene-Environment Interactions”The development of atopic asthma often results from the intricate interplay between an individual’s genetic predisposition and their environmental exposures. Genome-wide searches have been conducted to identify gene-environment interactions, particularly with factors like smoking status and allergic status, recognizing their significant roles as modifiers of asthma risk.[3] Despite these investigations, some studies have shown that the strongest evidence for interactions with smoking status (e.g., involving rs1007026 near MOCS1 and DAAM2) and allergic status (e.g., involving rs17136561 near TUBB2B) did not consistently reach genome-wide significance. [3]
Similarly, specific associations of SNPs on chromosome 9q21.31with asthma were examined in relation to current parental smoking and residential ambient ozone exposure, but no evidence for effect modification by these environmental factors was found.[7]These findings suggest that while both genes and environment are crucial, the specific mechanisms of their interaction can be subtle and complex, requiring further research to fully elucidate how genetic susceptibility is modulated by external triggers in atopic asthma.
Comorbidities and Phenotypic Overlap
Section titled “Comorbidities and Phenotypic Overlap”Atopic asthma frequently co-occurs with other atopic conditions, highlighting shared underlying biological pathways and genetic factors. Atopic dermatitis (AD), for instance, is often co-expressed with asthma, indicating a strong phenotypic overlap.[10] Several genetic loci, including IL6R, FLJ44477-USP38, and SUOX-IKZF4, demonstrate more significant associations in individuals diagnosed with both atopic dermatitis and asthma compared to those with atopic dermatitis alone, suggesting common genetic predispositions for these combined phenotypes.[17]
Allergic rhinitis, commonly known as hay fever, is another highly prevalent comorbidity with atopic asthma. This close association has led to the concept of “united airway disease,” which posits that inflammatory processes affecting the upper respiratory tract (rhinitis) and the lower respiratory tract (asthma) are interconnected.[18]The frequent co-occurrence of these allergic conditions underscores a broader atopic diathesis, where shared genetic and immunological mechanisms contribute to the susceptibility and manifestation of multiple allergic diseases, including atopic asthma.[12]
Biological Background
Section titled “Biological Background”Atopic asthma is a complex chronic inflammatory disease of the airways, characterized by bronchoconstriction and airflow obstruction, which arises from intricate interactions between genetic predispositions and environmental factors.[7] It has a significant prevalence and a chronic relapsing course, imposing substantial societal costs. [19]While often associated with atopy, particularly in childhood asthma, the direct causal role ofIgEproduction is questioned in many populations where a link between atopic sensitization and asthma symptoms is absent.[19]
Genetic Underpinnings and Regulatory Networks
Section titled “Genetic Underpinnings and Regulatory Networks”Asthma exhibits a strong genetic component, with heritability estimates ranging from 48% to 79%, highlighting the significant influence of inherited factors on disease risk.[7] Genome-wide association studies (GWAS) have been instrumental in identifying numerous susceptibility loci across different populations, confirming known genetic associations and uncovering new ones. [17] Specific genetic variants, such as those regulating ORMDL3expression, contribute to the risk of childhood asthma, while associations nearIL1RL1 and a deletion on chromosome 17q21 have also been identified. [1] Furthermore, the HLA-DRB1locus shows an association with quantitative traits underlying asthma, andHLA-DQhas been confirmed in the diagnosis of adult asthma, underscoring the role of immune-related genetic regions.[5]
Beyond specific genes, broader regulatory networks play a crucial role. For instance, the CTNNB1 (Catenin (cadherin-associated protein), beta 1) gene acts as a central “hub” within interconnected biological networks associated with dermatological and allergic disorders, including inflammatory and immunological diseases. [20] CTNNB1is vital for cell-cell junctions in epithelial tissues, forming adherens junctions, and is an important signaling pathway in airway smooth muscle growth.[20]The high interconnectivity of such hub genes suggests their functional and biological importance in the complex pathogenesis of asthma.
Epithelial Barrier Dysfunction and the Atopic March
Section titled “Epithelial Barrier Dysfunction and the Atopic March”A critical aspect of atopic asthma involves disruptions in epithelial barrier function, particularly within the skin and airways. Defects in barrier proteins such asFilaggrin (FLG) and serine proteases, specifically serine protease inhibitor, kazal type 5 (SPINK5), are recognized as major predisposing factors for atopic dermatitis, a condition frequently linked to asthma.[19]These barrier defects are central to the concept of the “atopic march,” where allergic sensitization often begins in the skin and subsequently progresses to involve the respiratory and gastrointestinal tracts, leading to conditions like asthma.[20]
Within the airway epithelium, a defective barrier contributes significantly to asthma pathophysiology. Studies have shown that patients with atopic asthma exhibit lower expression of epithelial alpha-catenin and E-cadherin, key components of cell-cell adhesion, which can compromise the integrity of the epithelial barrier.[20]This impaired barrier allows for increased exposure to allergens and environmental triggers, exacerbating the inflammatory response and contributing to airway hyperresponsiveness characteristic of asthma.
Immune Dysregulation and Inflammatory Processes
Section titled “Immune Dysregulation and Inflammatory Processes”The immune system’s dysregulation is central to atopic asthma, involving a cascade of molecular and cellular pathways.Interleukin 5 (IL5), a key cytokine, plays a significant role in linking the innate and acquired immune responses, particularly in promoting eosinophil activation and survival.[21] Elevated IL5levels are implicated in eosinophilic asthma, a severe form of the disease, and therapeutic approaches targetingIL5, such as Mepolizumab, have shown efficacy in reducing exacerbations in refractory cases. [22]
While IgEis often associated with atopy, its role as a primary cause of asthma is debated, with some research suggesting it may be a secondary effect rather than a causative agent.[19] However, other immune-related genetic factors, such as TNFhaplotypes, have been associated with asthma, pointing to broader inflammatory signaling pathways.[23]The interplay of these various biomolecules, including cytokines, receptors, and transcription factors, orchestrates the chronic inflammation and immune responses that drive the disease.
Airway Pathophysiology and Systemic Interactions
Section titled “Airway Pathophysiology and Systemic Interactions”At the organ level, atopic asthma primarily manifests in the respiratory system, characterized by chronic airway inflammation and bronchoconstriction, which together lead to airflow obstruction.[7]This inflammation involves the infiltration of various immune cells and the release of inflammatory mediators, contributing to airway hyperresponsiveness and remodeling. The disease often affects multiple body systems, exemplified by the concept of “united airway disease,” which highlights the close relationship between rhinitis and asthma, indicating an integrated respiratory system response to allergic triggers.[18]
Furthermore, the systemic consequences of atopic asthma extend beyond the airways, as evidenced by genetic loci showing overlapping effects on conditions like atopic dermatitis and psoriasis.[13]This suggests shared underlying biological mechanisms and pathways contributing to various allergic and inflammatory disorders. The functional classes of genes involved in asthma often relate to inflammatory and immunological diseases, reflecting complex tissue interactions and systemic immune responses that collectively drive the progression and manifestation of atopic asthma.[20]
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Epithelial Barrier Dysfunction and Cell Adhesion Signaling
Section titled “Epithelial Barrier Dysfunction and Cell Adhesion Signaling”Atopic asthma involves significant dysregulation of epithelial cell junctions and adhesion molecules, which are critical for maintaining the airway barrier. TheCatenin (cadherin-associated protein), beta 1 (CTNNB1) gene complex, a central hub in cellular networks, is vital for cell-cell junctions in epithelial tissues and the formation of adherens junctions. Dysfunction in this complex can impair the integrity of the airway epithelium, a critical factor in asthma pathogenesis.[20] Furthermore, E-cadherinplays a crucial role in controlling responses to allergens, suppressing the production of allergenic mediators, and fostering immune tolerance. Studies indicate that patients with atopic asthma often exhibit lower expression of epithelialalpha-catenin and E-cadherin, contributing to a compromised epithelial barrier that increases susceptibility to allergens and inflammation. [20] The importance of beta-cateninas a signaling pathway in airway smooth muscle growth further highlights its broad impact on airway remodeling in asthma.[20]
Immune Signaling and Inflammatory Cascades
Section titled “Immune Signaling and Inflammatory Cascades”The immune response in atopic asthma is characterized by specific signaling pathways that promote inflammation and allergic reactions. Interleukin-33 (IL33), detected in inflamed tissues and constitutively expressed in airway epithelial cells, acts as a key alarmin, activating nuclear factor κB (NF-κB) and mitogen-activated protein (MAP) kinases. This activation drives the production of Th2-associated cytokines, including interleukin-4, interleukin-5 (IL5), and interleukin-13, which are central to allergic inflammation. [24] The transcription factor GATA-3is essential and sufficient for the expression of these Th2 cytokine genes in CD4 T cells, orchestrating the allergic immune response.[25] Additionally, Interleukin 5serves as a critical link between innate and acquired immune responses, promoting eosinophil survival and activation, which are hallmarks of asthmatic inflammation.[21] Interferon regulatory factor 7 (IRF7) acts as a major hub connecting interferon-mediated responses, particularly in virus-induced asthma exacerbations, indicating its role in immune regulation during respiratory infections.[26]
Metabolic Dysregulation and Oxidative Stress
Section titled “Metabolic Dysregulation and Oxidative Stress”Metabolic pathways are increasingly recognized for their role in the pathophysiology of atopic asthma, contributing to inflammation and airway dysfunction. Genetic variants at the chromosome 17q21 locus, which are strongly associated with asthma, influence the expression ofORMDL3 and GSDMB. Research suggests that changes in the expression of homologous ORM genes in yeast lead to dysregulation of sphingolipid metabolism, implying a similar mechanism in humans that could modulate airway inflammation and present a potential therapeutic target. [24]Beyond sphingolipids, mitochondrial pathways are significantly implicated in allergic diseases, including allergic rhinitis, with a strong link to lower airway conditions like asthma. Studies show higher levels of reactive oxygen species and lower levels of reduced glutathione (an antioxidant) in allergic individuals, indicating heightened oxidative stress.[8] Mitochondrial dysfunction is a key contributor, and interventions with antioxidants that target mitochondria have been shown to reduce allergen-induced airway hyperreactivity and inflammation severity in models of allergic airway inflammation. [8]
Network Interactions and the Atopic March
Section titled “Network Interactions and the Atopic March”The development of atopic asthma involves complex, integrated, and interconnected biological networks that reflect a systemic predisposition, often described as the “atopic march.” This concept suggests that allergic disorders may begin in the skin and progress to the respiratory and gastrointestinal tracts.[20] Genome-wide analyses reveal hub genes, like CTNNB1, which interact with numerous other genes both upstream and downstream, highlighting their functional and biological importance within these networks. [20] These interconnected networks are related to dermatological or allergic disorders, particularly involving inflammatory and immunological diseases. The intricate crosstalk between various signaling pathways, such as IL33 activating NF-κB and MAPkinases, further illustrates the systemic nature of atopic disease. This hierarchical regulation and pathway crosstalk contribute to emergent properties of the disease, where the whole system’s dysfunction is greater than the sum of its individual components.[24]
Population Studies
Section titled “Population Studies”Global Prevalence and Demographic Patterns of Atopic Asthma
Section titled “Global Prevalence and Demographic Patterns of Atopic Asthma”Asthma, particularly its atopic form, represents a significant global health burden, with prevalence rates notably reaching 8.9% in the United States and continuing to increase in many countries worldwide.[7]Epidemiological studies have revealed distinct demographic patterns associated with atopic asthma. For instance, a large discovery cohort of asthmatic patients indicated that 54% were classified with childhood asthma (onset at or before 16 years), while 26% experienced later onset, highlighting varying age-of-onset distributions. Furthermore, atopy, defined by a positive skin prick test response to at least one common allergen, was observed in 59% of these asthmatics, underscoring the strong allergic component in a majority of cases.[1]
Beyond general prevalence, investigations into demographic factors like age and sex reveal specific trends within study populations. For example, cohorts such as the Children’s Hospital of Philadelphia (CHOP) and the Childhood Asthma Management Program (CAMP) show cases with mean ages ranging from 7.5 to 8.7 years, with a slight male predominance in some pediatric asthma case groups.[2]The interplay with other atopic conditions is also evident, as studies like one focusing on atopic dermatitis identified loci with overlapping effects on asthma, often utilizing controls not specifically screened as asthma-free to allow for unbiased analysis of complex endophenotypes such as “atopic dermatitis and asthma”.[13] Such approaches enable a deeper understanding of the shared genetic and environmental underpinnings of allergic diseases.
Large-Scale Cohort Investigations and Longitudinal Insights
Section titled “Large-Scale Cohort Investigations and Longitudinal Insights”Large-scale population cohorts and biobank studies are instrumental in understanding the natural history and genetic architecture of atopic asthma, providing valuable longitudinal data. The Avon Longitudinal Study of Children and Parents (ALSPAC), for example, is a population-based birth cohort that has extensively phenotyped children from birth through 21 years of age, utilizing questionnaires completed by caregivers and adolescents.[17] Similarly, the Western Australian Pregnancy Cohort (Raine) study, which recruited nearly 3,000 pregnant women, has followed their children for over two decades, collecting comprehensive health data. [17]These cohorts serve as critical resources for identifying temporal patterns of disease onset and progression, as well as for providing population-based controls in genetic association studies.
Several other prominent cohorts contribute to the understanding of atopic asthma. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase II, the British 1958 Birth Cohort, and the Swedish longitudinal birth cohort BAMSE have all been utilized as sources for population-based controls or replication datasets in various genetic studies.[2]The Analysis in Population-based Cohorts of Asthma Traits (APCAT) consortium further exemplifies this, integrating data from six population-based cohorts across Finland and the United States, including the Framingham Heart Study, to validate known genetic associations and discover novel ones. These comprehensive efforts, often involving thousands of individuals, allow for robust epidemiological and genetic investigations into the complex etiology of atopic asthma.[1]
Genetic Epidemiology and Ancestry-Specific Associations
Section titled “Genetic Epidemiology and Ancestry-Specific Associations”Genetic epidemiological studies have increasingly explored the role of ancestry and geographic variations in atopic asthma susceptibility, revealing both shared and population-specific genetic risk factors. While many large-scale genome-wide association studies (GWAS) have predominantly focused on individuals of European ancestry, identifying numerous risk loci for asthma[1] research has also expanded to diverse populations. For instance, a GWAS in Japanese populations identified HLA-DPas a susceptibility gene for pediatric asthma, with participants recruited from various cities and medical centers across Japan.[27] This suggests that certain genetic influences may be more pronounced or unique within specific ethnic groups.
Further highlighting ancestry-specific effects, studies have systematically analyzed genetic risk factors across European, African-American, and Hispanic asthmatic children. These investigations often employ affected offspring trio or family designs, which are particularly robust against potential confounding by population substructure that can arise in genetically diverse groups. [20]Another GWAS specifically implicated chromosome 9q21.31 as a susceptibility locus for asthma in Mexican children, demonstrating the importance of studying diverse populations to uncover the full spectrum of genetic contributions to disease risk.[7] Rigorous quality control measures, including screening for ancestry-informative markers and performing multidimensional scaling analysis of identity-by-state distances, are routinely applied to ensure that observed associations are not spurious due to population stratification. [28]
Methodological Approaches and Generalizability in Atopic Asthma Research
Section titled “Methodological Approaches and Generalizability in Atopic Asthma Research”The rigorous design and execution of population studies are paramount for generating reliable insights into atopic asthma. Common study designs include large-scale case-control GWAS, often involving thousands of participants, and longitudinal birth cohorts that track health outcomes over many years.[1] Sample sizes are frequently substantial, with discovery cohorts reaching over 5,000 individuals and replication datasets often including tens of thousands, as seen in consortia like APCAT, which aggregated data from 1,716 asthmatic patients and 16,888 controls. [1] This scale enhances statistical power and the generalizability of findings.
Representativeness and diagnostic precision are key considerations. While some studies recruit cases from tertiary clinics, potentially enriching for moderate-to-severe disease, controls are often drawn from population-based surveys to reflect general population prevalence.[13]Diagnosis of asthma typically relies on physician diagnosis, either through clinical examination or self-report via epidemiological questionnaires, and atopy is commonly defined by positive skin prick tests.[1]An important methodological choice in some studies is not to specifically select controls as “asthma-free,” which allows for unbiased analysis of overlapping phenotypes, such as atopic dermatitis and asthma, but requires careful interpretation of prevalence within control groups.[5] Furthermore, advanced genotyping platforms and sophisticated bioinformatic tools, such as imputation of HapMap SNPs and stringent quality control procedures, are consistently applied to ensure high data quality and mitigate issues like population stratification, thereby strengthening the validity of genetic associations. [28]
Frequently Asked Questions About Atopic Asthma
Section titled “Frequently Asked Questions About Atopic Asthma”These questions address the most important and specific aspects of atopic asthma based on current genetic research.
1. Why do I get asthma from pollen, but my friend doesn’t?
Section titled “1. Why do I get asthma from pollen, but my friend doesn’t?”Your susceptibility to allergens like pollen is strongly influenced by your genes, such as variants in IL33 or IL1RL1. These genes play a role in how your immune system reacts to environmental triggers, making some people more prone to allergic responses and atopic asthma than others, even in the same environment.
2. Will my kids definitely inherit my atopic asthma?
Section titled “2. Will my kids definitely inherit my atopic asthma?”While atopic asthma has a strong genetic component, your children won’tdefinitely inherit it. Many genes are involved, and they might inherit some risk factors but not others. Environmental exposures also play a crucial role, so having the genes doesn’t guarantee the condition.
3. Why do some asthma medicines work better for others than me?
Section titled “3. Why do some asthma medicines work better for others than me?”Your genetic makeup can influence how your body responds to different medications. Atopic asthma involves specific immune and inflammatory pathways, and genetic variations in genes likeIL6R can affect how you metabolize or react to treatments targeting these pathways, leading to varied effectiveness among individuals.
4. Is getting a DNA test useful for my asthma treatment?
Section titled “4. Is getting a DNA test useful for my asthma treatment?”A DNA test could offer insights into your specific genetic risk factors for atopic asthma, such as the predisposing variant on chromosome 11q13.5. This information might eventually help your doctor tailor more personalized diagnostic approaches or treatment strategies, as understanding your genetic profile can predict how you might respond to certain therapies.
5. My sibling has asthma, but I don’t; why are we different?
Section titled “5. My sibling has asthma, but I don’t; why are we different?”Even with shared parents, you and your sibling inherit different combinations of genes. Asthma risk involves many genes, likeORMDL3 or GSDMB, and environmental exposures also vary. This unique interplay of specific genetic variants and individual life experiences can lead to one sibling developing atopic asthma while the other does not.
6. Does my ethnic background affect my risk for atopic asthma?
Section titled “6. Does my ethnic background affect my risk for atopic asthma?”Yes, your ethnic background can influence your asthma risk. Genetic studies have often focused on specific ancestries, showing that genetic risk factors and their prevalence can differ across populations. This highlights the importance of broader research to understand how different genetic backgrounds contribute to atopic asthma globally.
7. Can I really overcome my family history of asthma with lifestyle changes?
Section titled “7. Can I really overcome my family history of asthma with lifestyle changes?”While you can’t change your inherited genetic predisposition, lifestyle adjustments and avoiding environmental triggers can significantly manage your risk and symptoms. Genetics set a baseline, but minimizing exposure to allergens and maintaining overall health can help mitigate the impact of those genetic factors.
8. Does my immune system really cause my asthma attacks?
Section titled “8. Does my immune system really cause my asthma attacks?”Yes, your immune system plays a central role in atopic asthma. Genetic variations in genes likeIL1RL1, IL18R1, and IL33influence how your immune system overreacts to common environmental allergens. This hypersensitivity triggers the inflammation and airway hyperresponsiveness characteristic of an asthma attack.
9. Why am I more sensitive to dust or pet hair than others?
Section titled “9. Why am I more sensitive to dust or pet hair than others?”Your heightened sensitivity to specific environmental allergens like dust or pet dander is often due to your genetic makeup. Genes involved in immune response and inflammation, such as HLA-DQ or SMAD3, can predispose your body to mount a stronger allergic reaction to these common triggers, leading to atopic asthma symptoms.
10. Why is it important to know if my asthma is “atopic”?
Section titled “10. Why is it important to know if my asthma is “atopic”?”Knowing if your asthma is atopic is crucial because it helps guide treatment. Atopic asthma is linked to allergic reactions, and understanding this distinction allows doctors to consider therapies that specifically target allergic pathways, which might be more effective for your condition compared to treatments for non-atopic forms.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Ferreira MA. “Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia.”Eur J Hum Genet. 2011; 19:694–700. PMID: 21150878.
[2] Himes, B.E. et al. “Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene.”Am J Hum Genet, vol. 84, no. 5, 2009, pp. 581-593.
[3] Ramasamy A. “Genome-wide association studies of asthma in population-based cohorts confirm known and suggested loci and identify an additional association near HLA.”PLoS One. 2012; 7:e44008. PMID: 23028483.
[4] Li, X. et al. “Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions.”J Allergy Clin Immunol, vol. 125, no. 2, 2010, pp. 328-335.
[5] Lasky-Su J, et al. “HLA-DQ strikes again: genome-wide association study further confirms HLA-DQ in the diagnosis of asthma among adults.”Clin Exp Allergy. 2012; 42:1724–33. PMID: 23181788.
[6] Duan, Q.L. et al. “A genome-wide association study of bronchodilator response in asthmatics.” Pharmacogenomics J, vol. 13, no. 5, 2013, pp. 450-456.
[7] Hancock DB, et al. “Genome-wide association study implicates chromosome 9q21.31 as a susceptibility locus for asthma in mexican children.”PLoS Genet. 2009; 5:e1000623. PMID: 19714205.
[8] Bunyavanich, S. et al. “Integrated genome-wide association, coexpression network, and expression single nucleotide polymorphism analysis identifies novel pathway in allergic rhinitis.”BMC Med Genomics, vol. 7, 2014, p. 55.
[9] Forno, E. et al. “Genome-wide association study of the age of onset of childhood asthma.”J Allergy Clin Immunol, vol. 129, no. 6, 2012, pp. 1530-1537.
[10] Ellinghaus D, et al. “High-density genotyping study identifies four new susceptibility loci for atopic dermatitis.”Nat Genet. 2013; 45:776–81. PMID: 23727859.
[11] Moffatt, M. F. et al. “A large-scale, consortium-based genomewide association study of asthma.”N Engl J Med, vol. 363, no. 13, 2010, pp. 1211-1221.
[12] Ferreira MA. “Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype.”J Allergy Clin Immunol. 2014; 133:402–9. PMID: 24388013.
[13] Weidinger S, et al. “A genome-wide association study of atopic dermatitis identifies loci with overlapping effects on asthma and psoriasis.”Hum Mol Genet. 2013; 22:4841–56. PMID: 23886662.
[14] Borish, L., and J. A. Culp. “Asthma: a syndrome composed of heterogeneous diseases.”Ann Allergy Asthma Immunol, vol. 101, no. 1, 2008, pp. 1-8.
[15] Kim, K. W., et al. “Genome-wide association study of recalcitrant atopic dermatitis in Korean children.”J Allergy Clin Immunol, vol. 136, no. 5, 2015, pp. 1308-1317.e10.
[16] Wenzel, S. E. “Asthma: defining of the persistent adult phenotypes.”Lancet, vol. 368, no. 9537, 2006, pp. 804-813.
[17] Ferreira, M.A. et al. “Genome-wide association analysis identifies 11 risk variants associated with the asthma with hay fever phenotype.”J Allergy Clin Immunol, vol. 133, no. 6, 2013, pp. 1564-1571.
[18] Rimmer J, Ruhno JW. “6: Rhinitis and asthma: united airway disease.”Med J Aust. 2006; 185:565–71. PMID: 17115970.
[19] Moffatt, M.F., et al. “A large-scale, consortium-based genomewide association study of asthma.”N Engl J Med, vol. 361, no. 13, 2009, pp. 1248–1259. PMID: 20860503.
[20] Ding, L. “Rank-based genome-wide analysis reveals the association of ryanodine receptor-2 gene variants with childhood asthma among human populations.”Hum Genomics, vol. 7, 2013.
[21] Takatsu, K., et al. “Interleukin 5 in the link between the innate and acquired immune response.” Adv Immunol, vol. 101, 2009, pp. 191–236. PMID: 19231596.
[22] Flood-Page, P. et al. “A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.”Am J Respir Crit Care Med, vol. 176, no. 11, 2007, pp. 1062-1071.
[23] Moffatt, M.F., et al. “Tumour necrosis factor haplotypes and asthma.”Hum Mol Genet, vol. 6, no. 4, 1997, pp. 551–554. PMID: 9097957.
[24] Moffatt MF, et al. “Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma.”Nature. 2007; 448:470–3. PMID: 17611496.
[25] Zheng, W., Flavell, R. A. “The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells.”Cell, vol. 89, no. 4, 1997, pp. 587–596.
[26] Myers, R. A. et al. “Genome-wide interaction studies reveal sex-specific asthma risk alleles.”Hum Mol Genet, vol. 23, no. 18, 2014, pp. 5021–5030.
[27] Noguchi, Emiko, et al. “Genome-wide association study identifies HLA-DP as a susceptibility gene for pediatric asthma in Asian populations.”PLoS Genetics, 2011. PMID: 21814517.
[28] Ferreira, Manuel A., et al. “Association between ORMDL3, IL1RL1 and a deletion on chromosome 17q21 with asthma risk in Australia.”European Journal of Human Genetics, 2010. PMID: 21150878.